Mumbai, India, August 2nd: Pinnacle Life Science, Subsidiary of Aarti Drugs Ltd, reached a milestone on July 29, 2024. The US Food and Drug Administration (USFDA) approved its oncology center in Baddi, Himachal Pradesh, India. The approval comes after a comprehensive review in April, which marks Pinnacle’s first step into the US market, expanding its global presence in the pharmaceutical industry.
The country’s leading oncology centers are focused on growth and product development, high-quality R&D, and high ethical standards and standards, with collaboration among competitors. With cancer cases expected to affect 1.57 billion by 2025, this comes at a highly anticipated time for Pinnacle LifeScience.
Pinnacle’s Baddi facility, which focuses on developing Oral Solid Dosage forms such as tablets and capsules, is a major pillar in the development of oncology treatments. With this FDA approval, Pinnacle Life Science meets its commitment to ensure the highest standards of quality and compliance required for the US market, confirming its dedication to providing high-quality pharmaceutical products. The center not only produces oncology drugs but also new molecules, offering a comprehensive portfolio including Anti-Cancer, Anti-Diabetic, Anti-Bacterial, Anti-Inflammatory, Anti-Fungal, Cardio- protectants, Vitamins and Sedatives, as the demand of the world market.
Video embedded:
“From the beginning, we’ve been committed to putting patients first by focusing on the latest life-saving drugs. I’ve seen one of my closest friends fight cancer, so we needed to make sure that our medicines were not only high quality but also cheap. Cancer is found in everyone. Vishwa Savla, Founder and Managing Director.
Expanding to 100 countries with 50+ API modules and 13 state-of-the-art devices, Aarti Drugs, their parent company, has helped Pinnacle manufacture 100 Million Oncology OSD Units annually. Pinnacle’s Oncology Facility began with a focus on quality and cost control. With the recent US FDA approval, the facility is now well positioned to compete in the global pharmaceutical market, advancing Pinnacle’s prospects as a market leader.
About Pinnacle:
Pinnacle Life Science Pvt. Ltd, a subsidiary of Aarti Drugs Ltd, is a global name in the pharmaceutical industry. Aarti Drugs Ltd. has an annual turnover of more than Rs. 5000 Cr dealing with many APIs and intermediates. This contributes to Pinnacle’s finished bonds and measurements, supported by two state-of-the-art cGMP compliant facilities in India. With a legacy of 35 years in healthcare and an annual production capacity of 3 billion tablets and 300 million capsules, the company has a complete collection of medicines for acute and chronic diseases, including specific areas such as Anti-Diabetic, Anti-Cancer and. Anti-Hypertensive drugs. The company’s global presence spans North and Latin America, Europe, Africa, Asia and beyond. The company works with more than 250 clients worldwide, emphasizing the growth of cooperation through various business models such as licensing, joint development, contract manufacturing and technology transfer.
Disclaimer: This article is a paid article and does not belong to Hindustan Times press/editorial. Hindustan Times does not endorse/endorse the content of the article/advertisement and/or the views expressed herein. Hindustan Times in any way, shall not be held responsible and/or liable in any way for all that is mentioned in the article and/or also regarding the opinion, opinion, publication(s), publication. (s), warranty(s) etc., stated/expressed in the same.
#Pinnacle #Life #Science #Subsidiary #Aarti #Drugs #Enters #Market #FDA #Approval